Daniel J. George, MD, professor of medicine and surgery at Duke Cancer Institute, discusses his rationale for choosing patients with renal cell carcinoma that should receive adjuvant sunitinib therapy.
Daniel J. George, MD, professor of medicine and surgery at Duke Cancer Institute, discusses his rationale for choosing patients with renal cell carcinoma (RCC) that should receive adjuvant sunitinib (Sutent) therapy.
Most importantly, George says to consider which patients will most likely benefit from this therapy. He says that by enriching patients at higher risk, physicians can focus even more on the patients more likely to benefit. When faced with a patient with node-positive disease, T4 disease, or high-grade or poor performance status disease, George is more likely to offer them this adjuvant therapy.
The challenge to overcome with these patients is deciding whether or not they can tolerate sunitinib for a year. Particularly with older patients or those that may be a little more on the fence, George will still discuss the option with them because of their higher risk of recurrence. There is a greater benefit associated with this adjuvant therapy.
See more from Targeted Oncology's discussion with Daniel J. George, MD, on the S-TRAC trial in renal cell carcinoma here:https://www.targetedonc.com/news/an-overview-of-strac-trial-analyses-in-patients-with-highrisk-rcc